International Journal of Clinical Case Reports, 2026, Vol.16, No.2, 92-107 http://medscipublisher.com/index.php/ijccr 107 Pizarro D., Romero I., Pérez-Mies B., Redondo A., Caniego-Casas T., Carretero-Barrio I., Cristóbal E., Gutiérrez-Pecharromán A., Santaballa A., D'Angelo E., Hardisson D., Vieites B., Matías-Guiu X., Estévez P., Guerra E., Prat J., Poveda A., López-Guerrero J., and Palacios J., 2023, The prognostic significance of tumor-infiltrating lymphocytes, PD-L1, BRCA mutation status and tumor mutational burden in early-stage high-grade serous ovarian carcinoma-a study by the spanish group for ovarian cancer research (GEICO), International Journal of Molecular Sciences, 24(13): 11183. https://doi.org/10.3390/ijms241311183 Rached L., Laparra A., Sakkal M., Danlos F., Barlesi F., Carbonnel F., De Martin E., Ducreux M., Even C., Pavec L., Michot J., Ribeiro J.M., Scotté F., Aix S.P., Lambotte O., Baldini C., and Champiat S., 2024, Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations, Cancer Treatment Reviews, 127: 102751. https://doi.org/10.1016/j.ctrv.2024.102751 Rausch M., Bartels K., and Leibold J., 2025, Immunotherapy in ovarian cancer: spatial functional genomics to unravel resistance mechanisms, Signal Transduction and Targeted Therapy, 10(1): 17. https://doi.org/10.1038/s41392-024-02110-w Rosario S.R., Long M.D., Chilakapati S., Gomez E.C., Battaglia S., Singh P., Wang J., Wang K., Attwood K., Hess S., McGray A., Odunsi K., Segal B., Paragh G., Liu S., Wargo J., and Zsiros E., 2024, Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer, Nature Communications, 15(1): 10609. https://doi.org/10.1038/s41467-024-54565-8 Shahnam A., Hitchen N., Nindra U., Manoharan S., Desai J., Tran B., Solomon B., Luen S., Hui R., Hopkins A., and Sorich M., 2023, Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies, European Journal of Cancer, 198: 113503. https://doi.org/10.1016/j.ejca.2023.113503 Shawky M., Choudhary C., Coleridge S., Bryant A., and Morrison J., 2025, Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer, The Cochrane Database of Systematic Reviews, 7: CD005343. https://doi.org/10.1002/14651858.cd005343.pub7 Shehaj I., Schröder M., Linz V., Krajnak S., Almstedt K., Stewen K., Schwab R., Hasenburg A., Schmidt M., and Heimes A., 2024, Occurrence and management of immunotherapy-associated adverse events in patients with gynecological cancers, Cancers, 16(7): 1371. https://doi.org/10.3390/cancers16071371 Tavares V., Marques I., De Melo I., Assis J., Pereira D., and Medeiros R., 2024, Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements, International Journal of Molecular Sciences, 25(3): 1845. https://doi.org/10.3390/ijms25031845 Vida R., Bartoletti M., Montico M., Rizzetto M., Zapelloni G., Corsetti S., Nicoloso M., Scalone S., Del Fabro A., Clemente N., Occhiali T., Lucia E., Reato C., Martella L., Caccin E., Poletto M., Tabaro G., Canzonieri V., Ditto A., and Puglisi F., 2025, Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer (OC): a meta-analysis of randomized trials, Cancer Treatment Reviews, 144: 103094. https://doi.org/10.1016/j.ctrv.2026.103094 Wang G., Yang H., Wang Y., and Qin J., 2025, Ovarian cancer targeted therapy: current landscape and future challenges, Frontiers in Oncology, 15: 1535235. https://doi.org/10.3389/fonc.2025.1535235 Wang L., Zhang Q., Wang X., Dong Z., Liu S., Wang Q., Zhang Z., and Xing J., 2025, Therapeutic landscape of ovarian cancer: recent advances and emerging therapies, Biomarker Research, 13(1): 103. https://doi.org/10.1186/s40364-025-00818-7 Whipman J.M., Jacob F., Heinzelmann V., and Bodenmiller B., 2025, Abstract 5540: Deconstructing the lethality of recurrence in ovarian cancer through multi-modal spatiotemporal analysis, Cancer Research, 85(8_Supplement_1): 5540. https://doi.org/10.1158/1538-7445.am2025-5540 Zhang C., Yang J., Chen S., Sun L., Li K., Lai G., Peng B., Zhong X., and Xie B., 2024, Artificial intelligence in ovarian cancer drug resistance advanced 3PM approach: subtype classification and prognostic modeling, EPMA Journal, 15(3): 525-544. https://doi.org/10.1007/s13167-024-00374-4
RkJQdWJsaXNoZXIy MjQ4ODYzNA==